血液凝固異常と腫瘍学 - Sysmex

1 Sysmex Journal Web 2004.. Eckhardt PETRI. Clinical & Scientific Affairs, Dade Behring Marburg GmbH, Box 1149, 35001 Marburg, Germany. Key Words D- .. 100 Trousseau ( ) .. 92 .. (DIC) .. (Venous Thromboembolism : VTE) . VTE . Monreal . 12 VTE .. VTE 20 . 38 .. Web 2004 11 24 . 1. Sysmex Journal Web 2004.. (Unfractionated Heparin : UFH, ) . ( Low Molecular Weight Heparin : LMWH) . UFH .. Lebeau UFH .. TNF IL- 10 LMWH . 1 1 1 . LMWH .. ( Tissue Factor : . TF, ) 1 . (PT) . (APTT) . TF .. TF . Duncan . (Markers of Coagulation and Haemostasis Activation : MOCHA) . MOCHA .. 12 . 2 D - F1 2 . TAT . 1 2 (F1 2) . - ( TAT ) .. TAT D- . 13 . ( eye of science ) TAT D- . 2. Sysmex Journal Web 2004. D- . D- . 21 . TAT D - FIGO . ( (FIGO) . D- ) . 14 15 C PAI ( . ) . D- . 22 . D- van D- Wersch F1 . 2 TAT D - . 16 17 F1 2 .. Geenen 23 . D- . 18 .. D- . D- . 19.

2 24 . D- . 20 .. D- Blackwell 2000. D- Genen 1997. D- Gaducci 1995. von Tempelhoff 1997. Mussoni 1986. F1+2, TAT, D- van Wersch 1995.. XIII van Wersch 1994. , D- Petri 1997, Petri 1998. Sakuragawa 1997. D- Edward 1993, Oya 1998. Seitz 1993, Bucheri 1997, TAT, D- . Taguchi 1997. 3. Sysmex Journal Web 2004.. VTE . 20 .. D - F1 2 TAT FM . Beer .. 1995 1996 11 . ( n 268 ) . 268 99 Sysmex . Dade Behring .. ( ) . TAT FM D- .. ) Sun NC, et al.: Hemostatic abnormalities in malignancy, a prospective study in one hundred eight patients. Part 1. Coagulation studies. Am J Clin Pathol, 71 : 10 16, 1979. ) Kemkes-Matthes B: Thrombohilie bei malignen Erkrankungen. Haemostaseologie, 17 : 23 29, 1997. ) Rickles FR, et al.: Venous thromboembolism in malignancy and malignancy in venous thromboembolism. Haemostasis, 28 ( ) : 43 49, 1998. ) Monreal M, et al.: Venous thromboembolism as first manifestation of cancer.

3 Sem Thromb Hemost, 25(2) : 131. 136, 1999. ) Petri E, et al.: Induction of angiogenesis in renal cell carcinoma? Investigation of regulatory cytokines and control (Beer 200225 ). P . (n = 196) (n = 71) ( ) (n = 20). TAT [ug/L] < F1+2 [nmol/L] < D-dimer [ug/L] 199 615 40 81 < FM [ug/mL] < 4. Sysmex Journal Web 2004. mechanisms in vivo and in vitro. J Urology, 157 : (Suppl. 4) cancer patients correlate with clinical stage and axillary lymph 1478 A, 1997. node status. J Clin Oncol, 18(3) : 600 608, 2000. ) Francis JL, et al.: Haemostasis and malignancy. Sem Thromb 17) Petri E, et al.: Thrombospondin (TSP) as a potential adhesion Hemost, 24(2) : 93 109, 1998. factor in tumor metastasis. Mol Biol Cell, 9 : 87A, 1998. ) Sakuragawa N, et al.: The extract from the tissue of gastric 18) Geenen RWF, et al.: Coagulation and fibrinolysis activation cancer as procoagulant in disseminated intravascular markers in prostatic carcinoma patients.

4 Eur J Clin Chem coagulation syndrome. Thromb Res, 10 : 457 463, 1977. Clin Biochem, 35 : 69 72, 1997. ) Mussoni L, et al.: Procoagulant and fibrinolytic activity of 19) Edwards CM, et al.: D-dimer a useful marker of disease stage human ovarian carcinoma cells in culture. Eur J Cancer Clin in colorectal cancer surgery. Br J Surgery, 69 : 101 103, Oncol, 22 : 373 380, 1986. 1993. ) Zacharski LR, et al.: heparin and cancer. Thromb Haemsot, 20) Oya M, et al.: Plasma D-Dimer Level in Patients with 80 : 10 23, 1998. Colorectal Cancer: Its role as a tumor marker. Surg Today, 10) Lebeau B, et al.: Subcutaneous heparin treatment increases 28 : 373 378, 1998. survival in small cell lung cancer. Cancer, 74 : 38 45, 21) Gadducci A, et al.: The measurement of Plasma D-dimer 1994. levels in the follow-up of patients with ovarian cancer. 11) Kakkar AK, et al.: Antithrombotic therapy in cancer.

5 BMJ, Anticancer Res, 15 : 2683 2686, 1995. 318 : 1571 1572, 1999. 22) von Tempelhoff GF, et al.: Blood coagulation and thrombosis 12) Duncan A, et al.: Markers of coagulation and haemostasis in patients with ovarian malignancy. Thromb Haemsot, 77 : activation ( MOCHA ) as indicators of unsuspected 456 461, 1997. malignancy. Thromb Haemost, (abstract), 1997. 23) van Wersch JWJ, et al.: Haemostasis activation markers in 13) Seitz R, et al.: Activation of coagulation and fibrinolysis in plasma of patients with benign and malign gynaecological patients with lung cancer: relation to tumour stage and tumors: a pilot study. Eur J Clin Chem Clin Biochem, 33 : prognosis. Blood Coag Fibrinolysis, 4 : 249 254, 1993. 225 229, 1995. 14) Buccheri G, et al.: Haemostatic abnormalities in lung cancer: 24) van Wersch JWJ, et al.: Coagulation Factor XIII in plasma of Prognosic implications.

6 Eur J Cancer, 33 : 50 55, 1997. patients with benign and mailgn gynaecological tumors. Eur J. 15) Taguchi O, et al.: Prognostic significance of plasma D-dimer Clin Chem Clin Biochem, 32 : 681 684, 1994. levels in patients with lung cancer. Thorax, 52 : 562 565, 25) Beer JH, et al: Coagulation markers predict survival in cancer 1997. patients. Thromb Haemost, 88 : 745 749, 2002. 16) Blackwell K, et al.: Plasma D-dimer levels in operable breast Coagulation Abnormalities and Oncology Eckhardt PETRI. Clinical & Scientific Affairs, Dade Behring Marburg GmbH, Box 1149, 35001 Marburg, Germany. Key Words Cancer, D-dimer, Venous Thromboembolism 5.